Suppressing Inflammation for the Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration: Dazdotuftide as a Potential New Multitarget Therapeutic Candidate
Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are major causes of blindness globally. The primary treatment option for DME and neovascular AMD (nAMD) is anti-vascular endothelial growth factor (VEGF) compounds, but this treatment modality often yields insufficient results, and...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/6/1562 |
| _version_ | 1827738470355828736 |
|---|---|
| author | Brice Nguedia Vofo Itay Chowers |
| author_facet | Brice Nguedia Vofo Itay Chowers |
| author_sort | Brice Nguedia Vofo |
| collection | DOAJ |
| description | Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are major causes of blindness globally. The primary treatment option for DME and neovascular AMD (nAMD) is anti-vascular endothelial growth factor (VEGF) compounds, but this treatment modality often yields insufficient results, and monthly injections can place a burden on the health system and patients. Although various inflammatory pathways and mediators have been recognized as key players in the development of DR and AMD, there are limited treatment options targeting these pathways. Molecular pathways that are interlinked, or triggers of multiple inflammatory pathways, could be promising targets for drug development. This review focuses on the role of inflammation in the pathogenesis of DME and AMD and presents current anti-inflammatory compounds, as well as a potential multitarget anti-inflammatory compound (dazdotuftide) that could be a candidate treatment option for the management of DME and AMD. |
| first_indexed | 2024-03-11T02:44:48Z |
| format | Article |
| id | doaj.art-71f07a5b10e642a39f2b044f504c331e |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-11T02:44:48Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-71f07a5b10e642a39f2b044f504c331e2023-11-18T09:25:05ZengMDPI AGBiomedicines2227-90592023-05-01116156210.3390/biomedicines11061562Suppressing Inflammation for the Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration: Dazdotuftide as a Potential New Multitarget Therapeutic CandidateBrice Nguedia Vofo0Itay Chowers1Department of Ophthalmology, Hadassah—Hebrew University Medical Center, Jerusalem 91120, IsraelDepartment of Ophthalmology, Hadassah—Hebrew University Medical Center, Jerusalem 91120, IsraelDiabetic retinopathy (DR) and age-related macular degeneration (AMD) are major causes of blindness globally. The primary treatment option for DME and neovascular AMD (nAMD) is anti-vascular endothelial growth factor (VEGF) compounds, but this treatment modality often yields insufficient results, and monthly injections can place a burden on the health system and patients. Although various inflammatory pathways and mediators have been recognized as key players in the development of DR and AMD, there are limited treatment options targeting these pathways. Molecular pathways that are interlinked, or triggers of multiple inflammatory pathways, could be promising targets for drug development. This review focuses on the role of inflammation in the pathogenesis of DME and AMD and presents current anti-inflammatory compounds, as well as a potential multitarget anti-inflammatory compound (dazdotuftide) that could be a candidate treatment option for the management of DME and AMD.https://www.mdpi.com/2227-9059/11/6/1562diabetic retinopathydiabetic macula edemaage related macular degenerationanti-inflammatory compoundsanti-vascular endothelial growth factordazdotuftide |
| spellingShingle | Brice Nguedia Vofo Itay Chowers Suppressing Inflammation for the Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration: Dazdotuftide as a Potential New Multitarget Therapeutic Candidate Biomedicines diabetic retinopathy diabetic macula edema age related macular degeneration anti-inflammatory compounds anti-vascular endothelial growth factor dazdotuftide |
| title | Suppressing Inflammation for the Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration: Dazdotuftide as a Potential New Multitarget Therapeutic Candidate |
| title_full | Suppressing Inflammation for the Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration: Dazdotuftide as a Potential New Multitarget Therapeutic Candidate |
| title_fullStr | Suppressing Inflammation for the Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration: Dazdotuftide as a Potential New Multitarget Therapeutic Candidate |
| title_full_unstemmed | Suppressing Inflammation for the Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration: Dazdotuftide as a Potential New Multitarget Therapeutic Candidate |
| title_short | Suppressing Inflammation for the Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration: Dazdotuftide as a Potential New Multitarget Therapeutic Candidate |
| title_sort | suppressing inflammation for the treatment of diabetic retinopathy and age related macular degeneration dazdotuftide as a potential new multitarget therapeutic candidate |
| topic | diabetic retinopathy diabetic macula edema age related macular degeneration anti-inflammatory compounds anti-vascular endothelial growth factor dazdotuftide |
| url | https://www.mdpi.com/2227-9059/11/6/1562 |
| work_keys_str_mv | AT bricenguediavofo suppressinginflammationforthetreatmentofdiabeticretinopathyandagerelatedmaculardegenerationdazdotuftideasapotentialnewmultitargettherapeuticcandidate AT itaychowers suppressinginflammationforthetreatmentofdiabeticretinopathyandagerelatedmaculardegenerationdazdotuftideasapotentialnewmultitargettherapeuticcandidate |